Howard Colman,
MD, PhD
Languages Spoken: English
Howard Colman, MD, PhD, has multiple clinical interests including the treatment of primary and metastatic brain tumors, and the diagnosis and management of neurologic complications of cancer. His clinical research is focused on the development and testing of new therapies for brain tumors. His laboratory interests include the identification of molecular markers of prognosis and treatment response in brain tumors and the role of tumors stem cells in the development and treatment resistance of brain tumors. He is a Jon M. Huntsman Presidential Professor in the Department of Neurosurgery, a member of the multidisciplinary Brain Tumor Research Team, and is Leader of the Center for Neurologic Cancers at Huntsman Cancer Institute (HCI) at the University of Utah. He is also an HCI investigator and a member of the Experimental Therapeutics program.
Clinical Locations
Clinic 2E, Neuro
801-585-0262
Board Certification and Academic Information
| Academic Departments | Neurosurgery
-
Professor Internal Medicine - Adjunct Professor Neurology - Adjunct Professor |
| Academic Divisions | Adult Neurosurgery Oncology |
| Board Certification | American Board of Psychiatry & Neurology (Neurology) United Council for Neurologic Subspecialties (Neuro-oncology) |
| Cancer Center Programs | Experimental Therapeutics |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.7/ 5
Care provider's explanation of condition/problem
4.6/ 5
Care provider's effort to include me in decisions
4.5/ 5
Wait time at clinic
3.8/ 5
Care provider's concern for questions & worries
4.6/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
November 20, 2020
HUNTSMAN CANCER CENTER
especially appreciated the PA's attentiveness and expertise
UofU Patient
November 19, 2020
HUNTSMAN CANCER CENTER
I think I have the best Doctor's available to anyone. thank you
UofU Patient
November 15, 2020
HUNTSMAN CANCER CENTER
provider suggested several options, but I didn't leave with that information in hand.
UofU Patient
October 19, 2020
HUNTSMAN CANCER CENTER
Good
UofU Patient
October 12, 2020
HUNTSMAN CANCER CENTER
Everything about the visit and personnel was like a well-oiled machine...
UofU Patient
October 07, 2020
HUNTSMAN CANCER CENTER
Everyone was amazing!
UofU Patient
August 19, 2020
HUNTSMAN CANCER CENTER
Highly recommend! Everyone cares about my current, previous, and future health.
UofU Patient
July 29, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
May 24, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
May 12, 2020
HUNTSMAN CANCER CENTER
good explanations were given
UofU Patient
April 27, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
April 14, 2020
HUNTSMAN CANCER CENTER
We were very happy to hear that the course of treatment was also recommended by Dr. Colman and his team. We appreciate the honesty, transparency and explanation of diagnosis that the team offered to us in a way we could understand. Thank you for confirming our treatment plans were exactly what we needed to do.
UofU Patient
April 10, 2020
HUNTSMAN CANCER CENTER
video visit - it was great.
UofU Patient
February 17, 2020
HUNTSMAN CANCER CENTER
Dr./care provider gave updates to my current condition, listened to my questions/concerns, included and explaineddecisions, and I highly recommend to others.
UofU Patient
December 14, 2019
HUNTSMAN CANCER CENTER
good
UofU Patient
November 23, 2019
HUNTSMAN CANCER CENTER
The entire TEAM was knowledgeable, attentive and compassionate.
UofU Patient
October 28, 2019
HUNTSMAN CANCER CENTER
good
UofU Patient
October 07, 2019
HUNTSMAN CANCER CENTER
they weren't very good to answer any Questions I had. Very friendly!
UofU Patient
October 07, 2019
HUNTSMAN CANCER CENTER
the best that has come out of terrible circumstances
UofU Patient
September 02, 2019
HUNTSMAN CANCER CENTER
The staight forward approach was much appreciated.
UofU Patient
July 16, 2019
HUNTSMAN CANCER CENTER
good
UofU Patient
June 19, 2019
HUNTSMAN CANCER CENTER
Great Doctor and PA!
UofU Patient
April 08, 2019
HUNTSMAN CANCER CENTER
good
UofU Patient
February 22, 2019
HUNTSMAN CANCER CENTER
good
UofU Patient
February 01, 2019
HUNTSMAN CANCER CENTER
Even though we have seen Dr. Colman on a regular basis he always takes the time to listen and answer all of our questions completely. His answers are always honest. He doesn't rush through the appointment or assume we understand. We receive best in class service every single time.
UofU Patient
January 27, 2019
HUNTSMAN CANCER CENTER
Dr. Colman is a very straight forward Doctor. When I asked him some tough questions and he provided no nonsense answers.
UofU Patient
May 20, 2018
I felt Dr. Colman could have taken more time looking over the MRI and explaining it to me.
UofU Patient
May 19, 2018
good
UofU Patient
May 06, 2018
I was very impressed by how prompt my questions were answered on MyChart.
UofU Patient
March 22, 2018
Doctor Coleman was also very good with my family
UofU Patient
February 20, 2018
This was my first time seeing Dr. Colman, I have seen Dr. Cohen in the past. I was very impressed with Dr. Colman's demeanor with me and his frankness in conversation.
UofU Patient
February 02, 2018
We always receive world class service. We trust our team and see them as partners in our journey.
UofU Patient
January 26, 2018
everything positive
UofU Patient
January 18, 2018
very good
UofU Patient
November 18, 2017
#1 in my books
UofU Patient
August 10, 2017
they pay attention to my comments and observations
UofU Patient
April 23, 2017
Dr. Colman used a lot of medical jargon that was hard for me to follow, especially for an early morning appointment (tired)
UofU Patient
January 23, 2017
The best!
UofU Patient
January 09, 2017
I have the very best team
UofU Patient
December 23, 2016
good experience but a bit overwhelming
UofU Patient
November 29, 2016
I really felt like I was heard and they were on my team for my treatment.
UofU Patient
October 23, 2016
always well taken care ofwith kiley, sean and dr coleman
UofU Patient
April 13, 2016
very good
UofU Patient
April 10, 2016
no complaints. I have complete confidence in this team
UofU Patient
February 11, 2016
I am one of those that typically gives strong critical feedback, especially negative in nature when it is appropriate. I don't have any related to this visit. The Doctor was courteous, on time, and straightforward.
UofU Patient
January 11, 2016
I am the second person in my family to meet with this doctor. He took great care to be sure we were comfortable.
UofU Patient
January 07, 2016
The Medical Doctor was very helpful and thoughtful. The Technician during the MRI "Rey" was wonderful. He made the MRI experience very pleasant!
UofU Patient
November 08, 2015
Your care providers have been great
UofU Patient
October 10, 2015
Dr. Coleman is very good at explaining everything
UofU Patient
September 23, 2015
I think Dr. Colman is one of the best Nero oncologist in the country. I fly once a year to see him. The trip cost me about $500.00 round trip. I could go to a doctor that is closer but I trust him. He doesn't sugar coat anything and I like that.
UofU Patient
September 21, 2015
A great team and they include the patient (and family) in the discussions.
UofU Patient
September 09, 2015
Very pleased with our experience and care.
UofU Patient
August 24, 2015
great care providers
UofU Patient
July 12, 2015
Very happy with Dr. Colman.
UofU Patient
July 05, 2015
So far life is good!
UofU Patient
July 02, 2015
Sean and Dr. Coleman are both professional and friendly, spend all the time we need and we like them and the care they give.
UofU Patient
June 12, 2015
i love love love Kylee, Shawn and Dr. Colman. they make a great team and ALWAYS go the extra mile for anything i need. They are all SUPER compassionate and caring. im glad i FINALLY found a great healthcare team for myself.
UofU Patient
May 19, 2015
good
UofU Patient
May 11, 2015
The opportunity to work with such an amazing team of professionals almost makes it worth it to have cancer.
UofU Patient
April 13, 2015
Dr. Colman is very friendly and always answers my questions and concerns. I feel very blessed to have him as my Dr.
UofU Patient
February 16, 2015
My team is great! I am so happy I finally got referred here.
UofU Patient
January 28, 2015
Very good Experience
UofU Patient
January 12, 2015
Dr. Colman has always fully answered any concerns or questions we might have. We have full trust in his care.
UofU Patient
January 10, 2015
Dr. Colman and his staff are awesome. I apologize but I don't know the doctor's name who saw me before Dr. Colman but he was great. He answered my questions and I could tell he was interested in how I was doing and what had gone on since the last time I was there. Dr. Colman was fantastic. I was very glad to hear that he is also over at the VA hospital. He showed me my tumor on the scan and answered all my questions. I trust him with my care.
UofU Patient
January 10, 2015
We had a very good experience with Dr. Colman, Sean PA, and nurse Kylee. All 3 were professional and caring. I am so happy I finally found a great team to take care of me. Healthcare these days seems lousy at best, but this team is PHENOMINAL!!!!!!! CANT SAY ENOUGH GOOD ABOUT THEM. THANK YOU THANK YOU THANK YOU!!!!!!!
UofU Patient
January 03, 2015
don't get me wrong my medical team is great and wouldn't trade them and I know they're busy but I'm busy too !!!!!
UofU Patient
November 01, 2014
Not impressed. When you have cancer their should always be some hope
UofU Patient
October 19, 2014
Dr and Assistant are exceptional. We feel very comfortable with them and are able to express our concerns and ask questions.
UofU Patient
October 04, 2014
We feel very confidante with Dr Colman
UofU Patient
October 03, 2014
Dr. Colman is a genius. He knows absolutely everything there is to know about brain tumors. He was great at educating us about the tumor and the medicine that would help it. I was slightly disappointed by our method of communication. He seemed to feel rushed and wanted to leave as soon as possible. He answered all of our questions, but a patient with a brain tumor needs time to process information.
UofU Patient
April 07, 2014
I have been to the clinic for 20 years but had a new doctor at this visit. Dr. Colman was very thorough, informative and patient.
UofU Patient
April 06, 2014
Dr Colman is great, his son played lacrosse with my son a few years ago, so he is willing to chat with me personally for a few minutes as well as being very professional in his medical care for me.
UofU Patient
March 30, 2014
I was very impressed with the quality of care at Huntsman. We have been to UCLA medical several times and we just moved to Utah and this was a vast improvement over the care we received at UCLA.
UofU Patient
March 15, 2014
just like the nursing staff, the PA/MD seemed to be in a hurry. However they seemed to be doing their best to answer all of my questions and not rush the appt
UofU Patient
February 03, 2014
I was very impressed that I transferred my care to Hunstman from IMC.
UofU Patient
October 30, 2013
The nurse, PA, and doctor were all fantastic and thorough and provided all the information I needed in a way that was easy to understand.
UofU Patient
July 06, 2013
love dr Colman. and his staff
UofU Patient
May 31, 2013
Very Positive Experience.
UofU Patient
May 27, 2013
I have the highest confidence in Dr Colman. He is an excellent physician.
UofU Patient
April 22, 2013
Dr Colman is excellent. I respect him and have a significant amount of confidence in his professional ability.
UofU Patient
March 28, 2013
I have a lot of confidence in my medical care team.
UofU Patient
February 18, 2013
Over the top. I left feeling hopeful and extremely confident with dr Coleman and the entire team
UofU Patient
January 22, 2013
I was very happy with the care I was given. I was especially surprised with the degree of time the doctor and pa gave me. Their concern for me was genuine and they made me feel relaxed and better able to understand what they were saying.
UofU Patient
November 19, 2012
Very clearly outlined the next few steps in my treatment
UofU Patient
November 19, 2012
All clinic staff (doctor, pa, and np) listened carefully to my questions, gave thorough answers and explanations, and made sure I understood next steps.
UofU Patient
November 05, 2012
I have recommended to many of my co-workers and family out of state about how awesome our experience was.
UofU Patient
August 20, 2012
Dr. Colman is awesome that is all that needs to be said.
UofU Patient
July 03, 2012
Between all the staff I was provided with almost 1.5 hours of care during my visit. This was outstanding. Dr Colman was very detail oriented and never seemed rushed - I really appreciated this. The PA seemed very knowledgeable, but very rushed.
UofU Patient
June 13, 2012
Dr. Howard Colman, has been very understanding, and communicates clearly, in a manner we can fully understand.
UofU Patient
April 27, 2012
Dr. Colman is always well informed on Sherry's latest MRI's and treatments. He gives us substantial input.
UofU Patient
March 14, 2012
Include me in the process of making a diagnosis and prescribing the right medication. They are not just doctors that tell you what to do because they said so. They are very involved in what's going on in the patient's mind.
UofU Patient
February 22, 2012
They addressed every concern.
UofU Patient
January 11, 2012
I am very grateful for the care that I have recieved from Dr. Howard Colman. I have the upmost confidence in them and the way they have treated my condition.
Howard Colman, MD, PhD, has multiple clinical interests including the treatment of primary and metastatic brain tumors, and the diagnosis and management of neurologic complications of cancer. His clinical research is focused on the development and testing of new therapies for brain tumors. His laboratory interests include the identification of molecular markers of prognosis and treatment response in brain tumors and the role of tumors stem cells in the development and treatment resistance of brain tumors. He is a Jon M. Huntsman Presidential Professor in the Department of Neurosurgery, a member of the multidisciplinary Brain Tumor Research Team, and is Leader of the Center for Neurologic Cancers at Huntsman Cancer Institute (HCI) at the University of Utah. He is also an HCI investigator and a member of the Experimental Therapeutics program.
Academic Locations
Huntsman Cancer Institute
801-587-4024
Board Certification and Academic Information
| Academic Departments | Neurosurgery
-
Professor Internal Medicine - Adjunct Professor Neurology - Adjunct Professor |
| Academic Divisions | Adult Neurosurgery Oncology |
| Board Certification | American Board of Psychiatry & Neurology (Neurology) United Council for Neurologic Subspecialties (Neuro-oncology) |
| Cancer Center Programs | Experimental Therapeutics |
Research Interests
- Brain Tumors
- Clinical Trials
- Role of Tumors Stem Cells in the Development and Treatment Resistance of Brain Tumors
- Development and Testing of New Therapies for Brain Tumors
- Identification of Molecular Markers of Prognosis and Treatment Response in Brain Tumors
Education History
| Fellowship | University of Texas M.D. Anderson Cancer Center Neuro-Oncology Fellow |
| Chief Resident | Washington University School of Medicine Neurology Chief Resident |
| Residency | Barnes-Jewish Hospital, Washington University School of Medicine Neurology Resident |
| Internship | Barnes-Jewish Hospital, Washington University School of Medicine Medicine Intern |
| Doctoral Training | Washington University School of Medicine Neuroscience Ph.D. |
| Professional Medical | Washington University School of Medicine Medicine M.D. |
| Undergraduate | Brown University Neural Sciences Sc.B. |
Selected Publications - Journal Articles
Journal Article
- Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA (2020). Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. (Epub ahead of print) Clin Cancer Res.
- Ellingson BM, Brown MS, Boxerman JL, Gerstner ER, Kaufmann TJ, Cole PE, Bacha JA, Leung D, Barone A, Colman H, van den Bent MJ, Wen PY, Yung WKA, Cloughesy TF, Goldin JG (2020). Radiographic Read Paradigms and the Roles of the Central Imaging Laboratory in Neuro-Oncology Clinical Trials. (Epub ahead of print) Neuro-Oncol.
- Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR (2021). A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro-Oncol, 22(10), 1505-1515.
- Werner CK, Nna UJ, Sun H, Wilder-Romans K, Dresser J, Kothari AU, Zhou W, Yao Y, Rao A, Stallard S, Koschmann C, Bor T, Debinski W, Hegedus AM, Morgan MA, Venneti S, Baskin-Bey E, Spratt DE, Colman H, Sarkaria JN, Chinnaiyan AM, Eisner JR, Speers C, Lawrence TS, Strowd RE, Wahl DR (2020). Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. Mol Cancer Ther, 19(10), 2163-2174.
- Holowatyj AN, Viskochil R, Ose D, Tingey B, Haaland B, Wilson D, Larson M, Feltz S, Lewis MA, Colman H, Ulrich CM (2020). Diabetes, Body Fatness, and Insulin Prescription Among Adolescents and Young Adults with Cancer. (Epub ahead of print) J Adolesc Young Adult Oncol.
- Cohen AL, Anker CJ, Johnson B, Burt LM, Shrieve DC, Salzman K, Jensen R, Boucher K, Colman H (2020). Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. J Neurooncol, 148(3), 577-585.
- Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C, Holland EC, Jenkins RB, Kleinschmidt-DeMasters B, Komori T, Kros JM, Louis DN, McLean C, Perry A, Reifenberger G, Sarkar C, Stupp R, van den Bent MJ, von Deimling A, Weller M (2020). cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol (Berl), 139(3), 603-608.
- Smith-Cohn M, Davidson C, Colman H, Cohen AL (2019). Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases. CNS Oncol, 8(4), CNS48.
- Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY (2020). Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery, 85(3), E607-E608.
- Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL (2019). Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol, 37(9), 741-750.
- Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, OBrien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM (2019). Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med, 25(3), 477-486.
- Hummel S, Kohlmann W, Kollmeyer TM, Jenkins R, Sonnen J, Palmer CA, Colman H, Abbott D, Cannon-Albright L, Cohen AL (2019). The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. BMC Cancer, 19(1), 190.
- Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB, Cancer Genome Atlas Research Network, Camargo F, Liang H (2018). Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Rep, 25(5), 1304-1317.e5.
- Ippen FM, Colman H, van den Bent MJ, Brastianos PK (2018). Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet? Am Soc Clin Oncol Educ Book, 38(38), 158-167.
- Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H, Holmen SL (2018). Mutant IDH1 Promotes Glioma Formation In Vivo. Cell Rep, 23(5), 1553-1564.
- Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja G (2018). Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. J Neurosurg, 128(4), 1133-1138.
- Colman H (2017). Toward more informative biomarker-based clinical trials in glioblastoma. Neuro-Oncol, 19(7), 880-881.
- Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen MC, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Nageswara Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognr L, Klekner A, Hortobgyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuon T, Schller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD (2016). Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis [Epub ahead of print]. J Clin Oncol, 34(21), 2468-2477.
- Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M (2016). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol, 18(4), 557-64.
- Karsy M, Guan J, Jensen R, Huang LE, Colman H (2016). The Impact of Hypoxia and Mesenchymal Transition on Glioblastoma Pathogenesis and Cancer Stem Cells Regulation. World Neurosurg, 88, 222-236.
- Ceccarelli M, et al TCGA Research Network, Colman H (2016). Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 146(3), 550-563.
- Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, Suki D, Colman H, Bhat KP, Sulman EP, Aldape K, Colen RR, Verhaak RG, Lu Z, Fuller GN, Huang S, Lang FF, Sawaya R, Hegi M, Majumder S (2015). Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. J Neurosci, 35(45), 15097-112.
- Yuan S, Lu Y, Yang J, Chen G, Kim S, Feng L, Ogasawara M, Hammoudi N, Lu W, Zhang H, Liu J, Colman H, Lee JS, Li XN, Xu RH, Huang P, Wang F (2015). Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism. Stem Cell Res Ther, 6(1), 198.
- Balasubramaniyan V, Vaillant B, Wang S, Gumin J, Butalid ME, Sai K, Mukheef F, Kim SH, Boddeke HW, Lang F, Aldape K, Sulman EP, Bhat KP, Colman H (2015). Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting. Oncotarget, 6(31), 31007-17.
- Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang FF (2015). Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells, 33(8), 2400-15.
- Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L, South ST, Abegglen LM, Schiffman JD, Colman H (2015). DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta Neuropathol Commun, 3, 34.
- The Cancer Genome Atlas Network (2015). Comprehensive and Integrative Genomic Characterization of Diffuse Lower Grade Gliomas DOI: 10.1056/NEJMoa1402121 *Includes Colman, H. N Engl J Med, 372(26), 2481-2498.
- Choi H, Gillespie DL, Berg S, Rice C, Couldwell S, Gu J, Colman H, Jensen RL, Huang LE (2015). Intermittent induction of HIF-1α produces lasting effects on malignant progression independent of its continued expression. PLoS ONE, 10(4), e0125125.
- Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS, CERN Foundation (2014). Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-Oncol, 17(3), 440-7.
- Karsy M, Neil JA, Guan J, Mahan MA, Colman H, Jensen RL (2015). A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus, 38(3), E4.
- Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H (2015). Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus, 38(3), E2.
- Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, MD Anderson Community Clinical Oncology Program, Brain Tumor Trials Collaborative (2015). Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol, 17(2), 266-73.
- Cohen AL, Colman H (2015). Glioma biology and molecular markers. Cancer Treat Res, 163, 15-30.
- Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med, 370(8), 699-708.
- Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D (2014). A high Notch pathway activation predicts response to gamma secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells, 32(1), 301-12.
- Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, Aldape K (2013). Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell, 24(3), 331-46.
Review
- Chen R, Cohen AL, Colman H (2016). Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. [Review]. Curr Treat Options Oncol, 17(8), 42.
- Karsy M, Guan J, Cohen A, Colman H, Jensen RL (2016). Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons. [Review]. Neurosurg Clin N Am, 27(2), 249-60.
- Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM (2015). Toward precision medicine in glioblastoma: the promise and the challenges. [Review]. Neuro Oncol, 17(8), 1051-1063.
Case Report
Editorial
- Colman H (2019). A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma. 21(1), 6-7.
Patent
- University of Texas M.D. Anderson Cancer Center, Colman H, Zhang L, Aldape K (2009). Multigene Assay to Predict Outcome in an Individual with Glioblastoma. U.S. Patent No. PCT/U808/55472. Washington, D.C.:U.S. Patent and Trademark Office.
Global Impact
Service
| 10/01/2015 | Member | GBM International Adaptive Trial Protocol Writing Committee. | China |